Source: Equities

Mironid Limited: Mironid Announces Closing of £4.3 Million $6.2 Million Series a Financing

By a News Reporter-Staff News Editor at Investment Weekly News -- Mironid Ltd, a leader in cell signalling directed drug development, announced the closing of its Series A funding round of £4.3 million ($6.2 million), which will support the Company's inter

Read full article »

Mironid Limited's Competitors | Mironid Limited's News | Mironid Limited's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

1-25

CEO

Neil Wilkie

CEO Approval Rating

84/100

Mironid is a Scotland-based biopharmaceutical company that researches and develops small-molecule therapeutics for the treatment of autosomal dominant polycystic kidney disease.